We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Electronic Notification of Teratogenic Risks (PREVENT)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 3, 2008
Last Update Posted: May 12, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Agency for Healthcare Research and Quality (AHRQ)
Information provided by:
University of Pittsburgh

This study will use a factorial design randomized controlled trial to (1)compare multi-faceted decision support (intervention) to streamlined clinical alerts (control) and (2) evaluate whether collecting information about women's risk of pregnancy using a networked tablet computer (intervention) is superior to the way clinicians usually collect this information (control).

Over the course of 1 year, we will abstract data from the electronic medical record when study clinicians prescribe teratogenic medications, conduct phone interviews with women prescribed medications by participating clinicians, and survey participating clinicians about their satisfaction with the decision support they receive. We will use this data to confirm our hypotheses that clinicians in the intervention groups will (1) prescribe fewer teratogenic medications, (2) be more likely to prescribe contraception when a teratogenic medication is prescribed, (3) have more patients report satisfaction with the counseling they received, and (4) report more satisfaction with the decision support they received.

Condition Intervention
Teratogens Abnormalities, Drug-Induced Contraception Other: Clinical decision support Other: stream-lined clinical alert

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Preconception Risk Evaluation Via Electronic Medical Record Notification of Teratogenic Risks

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Proportion of women prescribed potentially teratogenic medications with documented use of contraception [ Time Frame: 1 year ]

Enrollment: 2593
Study Start Date: October 2008
Study Completion Date: May 2011
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: multi-faceted decision support
Multi-faceted decision support
Other: Clinical decision support
multi-faceted decision support
Active Comparator: control
stream-lined clinical alert
Other: stream-lined clinical alert
electronic notification that a medication is potentially teratogenic


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women aged 18-45 seen at a participating primary care clinic

Exclusion Criteria:

  • Non-English speakers
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00766207

United States, Pennsylvania
Partners in Health
Delmont, Pennsylvania, United States, 15626
Partners in Health
Level Green, Pennsylvania, United States, 15085
Partners in Health
Murrysville, Pennsylvania, United States, 15085
General Internal Medicine Oakland (GIMO) Practice
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Agency for Healthcare Research and Quality (AHRQ)
Principal Investigator: Eleanor B Schwarz, MD, MS University of Pittsburgh
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Eleanor Bimla Schwarz, MD, MS, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00766207     History of Changes
Other Study ID Numbers: R18HS017093-01 ( U.S. AHRQ Grant/Contract )
1R18HS017093-01 ( U.S. AHRQ Grant/Contract )
First Submitted: October 1, 2008
First Posted: October 3, 2008
Last Update Posted: May 12, 2011
Last Verified: May 2011

Keywords provided by University of Pittsburgh:
Abnormalities, Drug-Induced

Additional relevant MeSH terms:
Congenital Abnormalities
Abnormalities, Drug-Induced